Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

Rhea-AI Summary

Actuate Therapeutics (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced its participation in the upcoming Citizens Life Sciences Conference 2025. The event will take place on May 7-8 in New York, NY.

Daniel Schmitt, President & CEO of Actuate, will deliver a presentation on Thursday, May 8, 2025, at 12:30 PM ET. The company, which specializes in developing treatments for difficult-to-treat cancers through GSK-3β inhibition, will make the presentation webcast available in their Investor section.

The management team will also conduct one-on-one meetings with investors during the conference. Interested investors should coordinate with their Citizens JMP representatives to schedule meetings.

Positive

• Participation in a major life sciences investor conference indicates institutional investor interest
• Management engaging in one-on-one investor meetings suggests active investor relations efforts

Negative

• None.

CHICAGO and FORT WORTH, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will present at the Citizens Life Sciences Conference 2025 taking place May 7-8 in New York, NY.

Citizens JMP Life Sciences Conference Presentation

Date:	Thursday, May 8, 2025
Time:	12:30 PM ET
Webcast Link:	click here

The webcast of the presentation will be accessible in the Investor section of the Actuate website.

The Actuate management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with management should contact their Citizens JMP representative.

About Actuate Therapeutics, Inc.

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DNA Damage Response (DDR) pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements about us, including our and other parties’ clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; preliminary and unpublished data may be subject to change following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; our reliance on third parties to conduct our non-clinical studies and our clinical trials ; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025 and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com 

FAQ

When is Actuate Therapeutics (ACTU) presenting at the Citizens Life Sciences Conference 2025?

Actuate Therapeutics (ACTU) will present at the Citizens Life Sciences Conference on Thursday, May 8, 2025, at 12:30 PM ET in New York, NY.

How can investors watch Actuate Therapeutics' (ACTU) Citizens Life Sciences Conference presentation?

Investors can access the webcast of Actuate Therapeutics' presentation through the Investor section of the Actuate website.

What is Actuate Therapeutics' (ACTU) main research focus in cancer treatment?

Actuate Therapeutics focuses on developing cancer therapies through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) for high-impact, difficult-to-treat cancers.

How can investors schedule meetings with Actuate Therapeutics (ACTU) management at the Citizens conference?

Investors interested in one-on-one meetings with Actuate Therapeutics management should contact their Citizens JMP representative.

What dates is the Citizens Life Sciences Conference 2025 being held?

The Citizens Life Sciences Conference 2025 is taking place from May 7-8, 2025, in New York, NY.